Clinical Trials
Multiple clinical trials evaluate L-aspartic acid across diverse therapeutic areas, including parenteral nutrition management, bipolar depression, acute lymphoblastic leukemia, and horizontal ridge augmentation. Spanning Phase 2, Phase 3, Phase 4, and unphased dental evaluations, these studies report recruitment statuses ranging from recruiting and completed to terminated. Sponsors include academic institutions such as Al-Azhar University and the Mayo Clinic collaborating with the National Institute of Mental Health, alongside industry entities including Baxter Healthcare Corporation and ERYtech Pharma.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06585852 | RECRUITING | Implant Dentistry |
Al-Azhar University |
2023-08-01 | |
| NCT01923480 | Terminated | Parenteral Nutrition (No Primary Condition Studied) |
Baxter Healthcare Corporation |
2013-07 | Phase 4 |
| NCT01042496 | Completed | Bipolar Depression |
Mayo Clinic|National Institute of Mental Health (NIMH) |
2009-12 | Phase 3 |
| NCT01523782 | Completed | Acute Lymphoblastic Leukemia |
ERYtech Pharma |
2009-04 | Phase 2 |
(data from https://clinicaltrials.gov, updated on 2024-09-19)
Compliance for Clinical Use
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).